Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Anti-Alpha-Galactosyl IgE Human ELISA

  • Regulatory status:RUO
  • Type:Capture ELISA, Biotin-labelled antibody
  • Other names:Anti-Alpha-Galactosyl Antibody
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

Availability on Request RD199429200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Capture ELISA, Biotin-labelled antibody



Sample Requirements

10 ul/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 8 °C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.04–1.28 U/ml

Limit of Detection

0.01 U/ml

Intra-assay (Within-Run)

n = 8; CV = 6%

Inter-assay (Run-to-Run)

n = 5; CV = 6.2%

Spiking Recovery


Dilution Linearity




  • The total assay time is less than 3.5 hours
  • The kit measures IgE anti-alpha-galactosyl antibodies in human serum
  • Assay format is 96 wells
  • Calibrator is human serum based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Immune Response, Infection and Inflammation, Immunology, Oncology


Carbohydrate moieties are frequently encountered in food and can elicit IgE responses. The recent work has identified a novel IgE antibody response to a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (α-Gal). IgE antibodies to galactose-α-1,3-galactose are capable of eliciting serious, even fatal, reactions. Alpha-Gal is a blood group substance of nonprimate mammals, a carbohydrate commonly expressed on a large number of nonprimate mammalian proteins. Some of the patients with positive skin tests to cat allergens have IgE antibodies specific for an oligosaccharide on cat IgA. The dominant human IgE epitope on cat IgA2 is the carbohydrate α-Gal. The oligosaccharide α-Gal is also present on the F(ab′)2 part of the monoclonal antibody cetuximab used in biological therapy for cancer. The immunoglobulin E (IgE) antibody response to the carbohydrate Galα1–3Galβ1–4GlcNAc-R is associated with allergies to red meat, cetuximab, and gelatin. The relationship between the exposure to an antigen and the subsequent allergic symptoms is usually obvious. However, two different and novel forms of anaphylaxis have now been associated with IgE to α-Gal, first of them being characterized by delayed onset of symptoms: (1) Delayed-onset anaphylaxis occurs 3 to 6 hours after ingestion of mammalian food products – meat (e.g. beef, pork, or lamb), organs, gelatin or milk of the animals that carry this oligosaccharide. The characteristic features of the syndrome of delayed anaphylaxis to red meat (DARM) are late onset of urticarial (hives), anaphylactic episodes, or angioedema, together with no immediate cause, a history of pruritic tick bites, and exposure to red meat 3 to 6 hours before the onset of symptoms. (2) This epitope has, in addition, been demonstrated to be responsible for potentially life-threatening anaphylactic reactions to cetuximab in patients who have specific IgE antibodies to α-Gal; in these patients, immediate-onset anaphylaxis during first exposure to intravenous cetuximab has been described. Although IgM, IgA and IgG antibodies to α-Gal (anti-α-Gal or anti-Gal) are widely expressed in humans, IgE anti-α-Gal antibodies are not. There is now extensive evidence that the primary impulse to start production of these IgE antibodies is a tick bite or parasitic infestation. The association between tick bites, red meat allergy and IgE to alpha-Gal has been reported from four continents to date. On the other hand, anti-α-Gal IgG and IgM antibodies could contribute to opsonization or blocking of α-Gal motifs on tick proteins, avoiding or reducing development of detrimental anti-α-Gal IgE response. Current evidence suggests that screening for IgE antibodies against the α-Gal epitope may help to identify patients who are at risk of anaphylaxis, including patients who start cetuximab treatment. Areas of investigation: Immunology, Allergology, Immune Response, Biological Therapy, Oncology

Related Products Docs